Neurons secrete neuropeptides from dense core vesicles (DCVs) to modulate neuronal activity. Little is known about how neurons manage to differentially regulate the release of synaptic vesicles (SVs) and DCVs. To analyze this, we screened all Caenorhabditis elegans Rab GTPases and Tre2/Bub2/Cdc16 (TBC) domain containing GTPase-activating proteins (GAPs) for defects in DCV release from C. elegans motoneurons. rab-5 and rab-10 mutants show severe defects in DCV secretion, whereas SV exocytosis is unaffected. We identified TBC-2 and TBC-4 as putative GAPs for RAB-5 and RAB-10, respectively. Multiple Rabs and RabGAPs are typically organized in cascades that confer directionality to membrane-trafficking processes. We show here that the formation of release-competent DCVs requires a reciprocal exclusion cascade coupling RAB-5 and RAB-10, in which each of the two Rabs recruits the other's GAP molecule. This contributes to a separation of RAB-5 and RAB-10 domains at the Golgi-endosomal interface, which is lost when either of the two GAPs is inactivated. Taken together, our data suggest that RAB-5 and RAB-10 cooperate to locally exclude each other at an essential stage during DCV sorting.
F ast synaptic transmission is mediated by the release of neurotransmitters from synaptic vesicles (SVs). In addition, neurons also release neuropeptides, hormones, and trophic factors from dense core vesicles (DCVs) to modulate neuronal activity and neurotransmission (1, 2) . DCVs and SVs are anatomically and functionally distinct secretory organelles (3, 4) . The mechanisms by which SVs and DCVs are differentially released by neurons are not clear.
In contrast to SVs, which can be recycled locally at the synapse, DCVs must be synthesized de novo in the cell body and replenished after exocytosis (5) . DCV biogenesis starts at the trans-Golgi network (TGN), where neuropeptide precursors along with their processing enzymes, SNAREs, and vacuolar ATPases are packaged into DCVs. They bud off from the TGN as immature (i)DCVs, which subsequently undergo an extensive maturation process (5) . During this maturation process, immature (i)DCVs are acidified. This activates furin-type proprotein convertases to proteolytically release active neuropeptides from their precursors. The active neuropeptides subsequently aggregate and form the dense core of DCVs. Mature (m)DCVs are formed after processing enzymes, SNAREs, required for homotypic iDCV fusion, and lysosomal proteins that have accidentally packaged into iDCVs are removed through sorting to the endosomal-lysosomal system (6) . mDCVs competent for regulated secretion are then transported into the axon to the sites of release. DCVs and SVs require different conditions for exocytosis (7) (8) (9) . However, despite their importance for the regulation of neuronal activity, very little is known about the molecular machinery, which differentially regulates DCV release.
Rab GTPases are master regulators of intracellular trafficking and have been shown to regulate SV release (10, 11) . They are molecular switches that cycle between an active GTP-bound form and an inactive GDP-bound form. Through interactions with effector proteins, Rab GTPases control various steps of vesicular transport such as budding, tethering, and fusion (10) . The activity state of Rab GTPases is regulated by auxiliary proteins called guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), which facilitate their activation and inactivation, respectively (12) . The human genome encodes over 60 Rab proteins (13) . The actions of many of these Rabs have been shown to be organized in cascades. In a Rab-conversion cascade, a single Rab activates a secondary Rab by recruiting its respective GEF (14, 15) . In contrast, during a Rab-exclusion cascade, a single Rab inactivates a secondary Rab by recruiting its respective GAP (16) .
In a previous study, we showed that the Golgi-localized GTPase RAB-2 is a key regulator of neuronal DCV maturation in Caenorhabditis elegans (17, 18) . We aimed here to identify additional Rabs that specifically regulate DCV biogenesis and secretion. By systematically testing all 22 Rab GTPases in C. elegans, we found that rab-5 and rab-10 mutants display severe defects in DCV but not SV release. This defect seems to occur because of a lack of reciprocal action of these Rabs on each other, through two specific GAP proteins, TBC-2 (RAB-5 GAP) and TBC-4 (RAB-10 GAP). DCV secretion from cholinergic motoneurons was assayed using a transgenic strain (nuIs183) expressing the proneuropeptide NLP-21 tagged to YFP (19) exclusively in dorsally projecting cholinergic motoneurons. This strain has been successfully used to assay DCV biogenesis and release (17) (18) (19) . At the trans-Golgi, the proneuropeptide NLP-21-YFP fusion is packaged into DCVs, where it is subsequently processed into active neuropeptides and soluble YFP. YFP-labeled DCVs are then transported to axonal release sites. After fusion, the soluble YFP is released into the body cavity. Here, it is constitutively endocytosed by macrophage-like cells, called coelomocytes. The YFP fluorescence in coelomocytes can, therefore, be used as an indirect readout for DCV release (Fig. 1A) . To identify Rabs that are regulating DCV release, we screened all viable rab mutants for defects in NLP-21-YFP secretion resulting in low coelomocytes fluorescence (Fig. 1B and Fig. S1 ). Rab GTPases, where the respective mutant was lethal or not available, were analyzed by RNAi or by neuronal expression of a constitutively active, GTP-bound mutant form (Fig. 1B) . As a positive control, we used Author contributions: N.S., M.S., M.H., B.D.G., S.O.R., A.G., and S.E. designed research; N.S., M.S., M.H., J.H., J.F.L., C.O., S.K., S.O.R., and A.G. performed research; N.S., M.S., M.H., J.H., and S.O.R. contributed new reagents/analytic tools; N.S., M.S., M.H., J.H., J.F.L., C.O., and S.O.R. analyzed data; and N.S., M.S., S.O.R., and S.E. wrote the paper.
unc-31/CAPS mutants, which are known to have defects in DCV release (20) . In this screen, we specifically identified RAB-5 and RAB-10 to be required for DCV secretion. DCV secretion was drastically reduced by around 83.24 ± 4.42% when a constitutively active, RAB-5 Q78L, mutant was expressed pan-neuronally or specifically in dorsally projecting cholinergic DA/DB motoneurons that also express the DCV marker NLP-21-YFP ( Fig. 1 B-E) . Similarly, expression of constitutively active RAB-10 Q68L also led to strongly impaired DCV secretion, whereas DCV release was completely abolished in the rab-10 (ok1494) deletion mutants ( Fig.  1 B-E) . This DCV secretion defect of rab-5 and rab-10 mutants was also confirmed using another DCV marker, the insulin-like neuropeptide INS-22-YFP (19) (Fig. S2) .
Whereas the secreted DCV-derived YFP, as measured by the coelomocyte fluorescence, was dramatically decreased, the YFP intensity of dorsal axons appeared normal in rab-5 and rab-10 mutants. This suggests that the number of DCVs at release sites is unaffected in these mutants. This observation was confirmed by high-pressure freeze electron microscopic (HPF-EM) analysis, which showed normal DCV numbers at axonal release sites with a similar distribution and morphology compared with wild type (Fig. S3) .
Because both secretion assays for NLP-21-YFP and INS-22-YFP are indirect assays, which rely on functional coelomocytes, it is conceivable that mutants affecting coelomocyte endocytosis would also display decreased coelomocyte YFP intensities. To demonstrate that coelomocyte function is unaffected in rab-10 mutants or by neuronal expression of rab-5 Q78L, we analyzed the coelomocyte uptake of soluble Texas Red-conjugated BSA (TR-BSA) injected into the body cavity (21) . Neither uptake nor the kinetics of endocytosis was affected in rab-5 Q78L and rab-10 mutants (Fig. S4 ). This demonstrates that rab-5 and rab-10 mutant motoneurons display specific DCV-secretion defects.
To ensure that the observed DCV-secretion defects were cellautonomous, we conducted tissue-specific knockdown of RAB-5 and RAB-10 by RNAi exclusively in the DA/DB cholinergic motoneurons and assessed for changes in NLP-21-YFP secretion (Fig. S5 D-F) . In accordance with the mutant analysis, tissuespecific knockdown of rab-5 and rab-10 phenocopied the defect in NLP-21-YFP secretion with decreased YFP levels in coelomocytes (87.22 ± 4.76% and 99.99 ± 0.00%, respectively) ( Fig. 1  C-E) . Furthermore, transgenic lines expressing mCherry-rab-10 exclusively in the DA/DB motoneurons rescued the DCV secretion defect in rab-10 mutants (Fig. 1 C-E) . These data suggest that RAB-5 and RAB-10 are required cell-autonomously in cholinergic motoneurons to regulate DCV release.
Synaptic Ultrastructure and SV Release Are Unaffected in rab-5 and rab-10 Mutants. RAB-5 and RAB-10 could be required for the release of SVs and DCVs. To exclude that RAB-5 and RAB-10 are required for SV release and synapse morphology, we initially analyzed two different SV markers, GFP-SNB-1 (synaptobrevin) and YFP-RAB-3. Both markers localize to SVs at synapses and can be viewed as discrete puncta in the dorsal nerve cord (DNC) axons when expressed in DA/DB cholinergic motoneurons. Each puncta highlights a neuromuscular synapse (22) . Fluorescence intensities of puncta, puncta number, and puncta size of GFP-SNB-1 and YFP-RAB-3 were not different compared with wild type. These data suggest that SVs are localized correctly and that SV-containing synapses are largely unaffected ( Fig. S3 A and B) . To show that the synapse structures are not altered in rab-5 and rab-10 mutants, we analyzed presynaptic terminals using HPF-EM. Ultrastructural analysis of neuronal cell bodies, neuronal Golgi complexes, and synapses revealed no major alterations in their morphology ( Fig. S3C and Fig. S6 ). In addition, the number and distribution of SVs at active zones of cholinergic motoneurons were also analyzed. No changes in SV numbers or in SV distributions were observed in rab-5 and rab-10 mutants (Fig. S3D) .
To assess the integrity of SV release, all strains were tested electrophysiologically for changes in evoked postsynaptic currents (EPSCs). For this purpose, rab-5 and rab-10 mutants were crossed into a strain expressing channelrhodopsin-2 in the cholinergic motoneurons. Photo-evoked responses revealed no changes in EPSCs (Fig. S3E ). All together, these data suggest that RAB-5 and RAB-10 are indeed factors specific for DCV release and not required for SV exocytosis.
RAB-10 Localizes to the Golgi-Endosomal Interface in Motoneurons.
It has been shown that in the C. elegans intestine, RAB-5 localizes to the endo-lysosomal system (23, 24) , and RAB-10 localizes to recycling endosomes (25) . However, the precise localization of RAB-10 in C. elegans motor neurons remained unclear. Therefore, a detailed mapping of RAB-10 localization in C. elegans ventral nerve cord (VNC) neurons was conducted. Fluorescently labeled RAB-10 displayed partial overlap with markers for Golgi (Mannosidase II), endosomes (2xFYVE), and iDCVs (Syntaxin-6). No overlap was found with the ER marker cytochrome b 5 (CB5) or the early Golgi/Coat protein complex I (COPI) vesicle marker (εCOP) ( Fig. 2A) . In motoneuron axons mCherry-RAB-10 was largely diffuse and only partially colocalized with presynaptic markers, such as SV marker (YFP-RAB-3) and DCV marker (NLP-21-YFP) (Fig.  2B) . DCVs are generally fewer in number at the active zone compared with SVs. Thus, it is likely that the partial localization of mCherry-RAB-10 at synaptic sites might suggest that RAB-10 is present on axonal DCVs. Interestingly, a recent proteomic analysis of DCVs enriched from vertebrate neurons also identified Rab10 (4). However, the strongest mCherry-RAB-10 signal was observed in motoneuron cell bodies where it partially colocalized with the DCV marker NLP-21-YFP (Fig. 2C) , further suggesting that RAB-10 may be present on DCVs. We then analyzed the localization of RAB-10 relative to RAB-5. In cell bodies, mCherry-RAB-10 and YFP-RAB-5 only weakly overlapped and mostly localized to adjacent domains in close proximity ( Fig. 2D ; see also Fig. 5, below) . These data suggest a function of RAB-5 and RAB-10 for DCV secretion at the Golgi-endosomal interface in cell bodies.
Rab GAP Mutants tbc-2 and tbc-4 Display DCV Secretion Defects Similar to rab-5 and rab-10. The function of Rab GTPases is regulated by GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs) (26) . Whereas the Rab GEFs are very diverse on the sequence level, most Rab GAPs contain a clearly identifiable TBC (tre-2/cdc16/Bub2) domain. To identify possible RAB-5 and RAB-10 GAPs involved in DCV release, we systematically screened TBC domain-containing Rab GAP mutants for their involvement in regulating NLP-21-YFP secretion. The C. elegans Rab GAP mutants, tbc-2 and tbc-4, displayed severe defects in DCV release similar to rab-5 and rab-10 mutants, respectively. Both an early-stop allele, tbc-2 (qx20), and a deletion allele, tbc-2 (tm2241) (23), had reductions in coelomocyte YFP intensities by 71.36 ± 14.10% and 81.01 ± 4.00%, respectively, closely matching rab-5 Q78L mutants (83.24 ± 4.42%). Similarly, the coelomocyte YFP intensities were almost abolished in the two tbc-4 deletion alleles, tbc-4 (ok2928) and tbc-4 (tm3255), by 94.64 ± 2.10% and 95.82 ± 1.39%, respectively, phenocopying rab-10 mutants (Fig. 3A) . As in the case with rab-10, neuronspecific expression of tbc-2 and tbc-4 restored DCV secretion. In contrast, neuron-specific expression of catalytically inactive TBC domain mutants TBC-2 R689A and TBC-4 R155A were unable to rescue DCV-secretion defects in tbc-2 and tbc-4 mutants. This suggests that the GAP activity of TBC-2 and TBC-4 is essential for DCV secretion (Fig. 3A) .
To exclude that tbc-2 and tbc-4 mutants affect synapse structure and synaptic vesicle release, we tested for defects in SV numbers, distribution, localization, and release by HPF-EM and electrophysiology. Analysis revealed that all measured properties of SVs were unaffected in tbc-2 and tbc-4 mutants (Fig. S3 A-E) . These data suggest that the synaptic ultrastructure and SV release are unaltered in tbc-2 and tbc-4 mutants, similar to rab-5 and rab-10 mutants. It is likely that TBC-2 and TBC-4 regulate RAB-5 and RAB-10 activity, respectively, for DCV release in neurons.
TBC-4 Is a Putative GAP for RAB-10. Recently, TBC-2 has been indeed identified as a RAB-5-specific GAP (23) . Therefore, given our data, it is likely that TBC-4 may be a RAB-10-specific GAP. TBC-4 contains an N-terminal TBC domain [106-316 aa; Simple Modular Architecture Research Tool (SMART) prediction] and three coiled coil (CC) domains at its C terminus (Fig. S7) . To test whether TBC-4 binds to RAB-10, we used the yeast two-hybrid (Y2H) system, which has previously been used successfully to identify functional Rab-GAP pairs (27) . The constitutively GTPbound form of RAB-10 Q68L exclusively binds to the catalytically inactive TBC-4 R155A mutant but not to the catalytically active full-length TBC-4 (Fig. 3C) . Furthermore, the constitutively inactive, GDP-bound form of RAB-10 T23N did not interact with TBC-4 R155A (Fig. 3D ). An analysis of the localization of RAB-10 with respect to TBC-4 demonstrated that they colocalize in the cell body to discrete puncta near the Golgi (Fig. 3F) . Therefore, it is likely that TBC-4 is indeed a GAP for RAB-10. In addition, TBC-4 is similar to the human TBC domain-containing oncogene Evi5 (28) and Evi5-like (Fig. S7) , for which weak Rab10-GAP activity could be demonstrated (29) .
Interestingly, GTP-bound forms of RAB-8 and RAB-11.1 were also found to interact with TBC-4, albeit with the CC domain located within the first 100 aa before the TBC domain (identified with SMART after alignment with TBC-4 orthologs) (Fig. 3E and Fig. S7 ). This suggests that TBC-4 may also be an effector for RAB-8 and RAB-11.1, although it is unlikely that these interactions are required for DCV release, because depletion of rab-8 or rab-11.1 revealed no DCV-secretion defects (Fig. 1B) . Moreover, RAB-8 and RAB-11.1 do not bind the TBC domain directly, so it is rather unlikely that TBC-4 might be a GAP for RAB-8 and RAB-11.1.
Two Effectors of RAB-5 and RAB-10 Phenocopy DCV-Release Defects.
Activated Rab GTPases bind or recruit effector proteins, which then exert downstream functions (30) . Therefore, we analyzed whether known RAB-5 and RAB-10 effectors are required for DCV secretion. Cell type-specific RNAi of the RAB-5 effector rabn-5 (rabaptin-5), as well as the RAB-10 effector ehbp-1 (31, 32), yielded no changes in NLP-21-YFP levels in the DNC axons but displayed a severe decrease in YFP fluorescence levels in the coelomocytes (rabn-5: 67.25 ± 14.80%; ehbp-1: 99.00 ± 0.20%), similar to rab-5 and rab-10 mutants, respectively (Fig. 4A) . The observed phenotype was specific to these two effectors, because other known effectors such as early endosomal antigen-1 (EEA-1) did not reveal any DCV-release defects (Fig. 4A) . These data suggest that there are two specific Rab-effector pairs required for DCV release. For directed membrane transport, Rab-effector complexes have been shown to be linked serially to form cascades. In such a cascade, a first Rab GTPase either activates or inactivates a second Rab by recruiting its GEF or GAP (15, 16) . To determine whether a similar cascade existed between RAB-5 and RAB-10, we assayed possible interactions between TBC-2, RABN-5, TBC-4, and EHBP-1 by Y2H. We detected a specific interaction between the RAB-5 effector, RABN-5, and the presumptive RAB-10 GAP, TBC-4 (Fig.  4B) . The RABN-5-binding domain of TBC-4 was confined to its C-terminal CC domain (TBC-4, 377-825 aa) (Fig. 4B) . This interaction was also confirmed by coimmunoprecipitation in COS7 cells (Fig. 4C) . In contrast, the N-terminal CC domains of RABN-5 (1-292 aa) bind to TBC-4 (Fig. 4B) . This TBC-4-binding domain of RABN-5 is distinct from its RAB-5-interaction domain, which is located at the C terminus of RABN-5 (Fig. 4B ). Because these binding domains are nonoverlapping, it is likely that activated, GTPbound RAB-5 and TBC-4 can simultaneously interact with RABN-5. As expected from their direct interaction, TBC-4 and RABN-5 colocalized to discrete puncta in motoneuron cell bodies (Fig. 4D) . Interestingly, further Y2H analysis showed that active, GTP-bound RAB-10 also interacts with the RAB-5 GAP, TBC-2 (Fig. 4E) . Wild-type TBC-2 also interacted with RAB-8, RAB-18, and RAB-35. However, depletion of neither of these Rab GTPases showed defects in DCV secretion (Fig. 1B) . It is, therefore, unlikely that these interactions are required for DCV release.
Reciprocal Exclusion of RAB-5 and RAB-10 by GAP Recruitment. Our results suggest that active RAB-5 would recruit the RAB-10 GAP, TBC-4, via Rabaptin-5 and that active RAB-10 would recruit the RAB-5 GAP, TBC-2. Thus, a domain of active RAB-5 would exclude RAB-10, whereas a RAB-10 domain would reciprocally exclude RAB-5 (Fig. 5G) . This exclusion cascade would explain how two distinct Rab domains can be generated from a mixed precursor and then stably maintained in close proximity to each other (Fig. S8) .
To directly test the reciprocal recruitment of the GAP in vivo, we expressed the dominant-active or -inactive variants of RAB-10 and RAB-5 and analyzed their ability to recruit TBC-2 and TBC-4, respectively ( Fig. 5 A and B) . As predicted by our Y2H data, active RAB-5 was localized to organelles where the RAB-10 GAP, TBC-4, was strongly recruited (Fig. 5 B and C) . Conversely, active RAB-10 recruited TBC-2 ( Fig. 5 A and C) . The two GAPs were much more diffusely distributed when coexpressed with the dominant-inactive Rabs, confirming that their localization depends upon the activity of these Rabs (Fig. 5 A-C) . To test whether the recruitment of the TBC-2 and TBC-4 GAPs set up exclusive nonoverlapping RAB-5 and RAB-10 domains, we compared the relative localization of RAB-5 and RAB-10 in wildtype and tbc-2 or tbc-4 mutant backgrounds. As expected by the exclusion model, we observed that YFP-RAB-5 and RFP-RAB-10 significantly colocalized in the absence of TBC-2 or TBC-4, whereas in wild-type neuronal cell bodies, both domains are segregated (Fig. 5 D-F) . To determine whether this was attributable to the presence of RAB-5 and RAB-10 exclusively in different organelles in the wild type, or to the presence of separate domains on single organelles, we averaged the images of RAB-5-containing organelles for all three different genotypes (Fig. 5E ). This procedure, when performed in absence of TBC-2 or TBC-4, provided an average organelle where the green (RAB-5) and red (RAB-10) signals correlated almost perfectly. However, in the wild-type background, the red and green signals were shifted by ∼210 nm. Because this value is substantially below the average organelle diameter (∼570 nm in this experiment), and because our imaging resolution is below the organelle size, this value indicates that separate Rab domains coexist on the same organelles.
Discussion
We have demonstrated that RAB-5 and RAB-10 are regulators of neuronal DCV release in C. elegans. Although almost all previous reports have placed RAB-5 and RAB-10 as a candidate required solely in the endocytic and recycling pathways (10, 15, 25 33) , we propose that they have a function in controlling DCV secretion.
Previous studies have shown that PKC-1 selectively disrupts DCV release. Using a similar assay in C. elegans, it has been shown to reduce DCV secretion by about 50% (19) . Interference with the RAB-5/RAB-10 cascade, however, reduces DCV release by 83% in the case of rab-5 and literally abolishing release in the case of rab-10. Whereas impairment of UNC-13 affects DCV secretion, it also abolishes SV release (34, 35) . UNC-31/CAPS has been suggested to only regulate DCV release in C. elegans. However, analysis of EPSCs in unc-31 mutants demonstrated a decrease to about 50% of wild-type levels (20, 35) . Initially, the decrease in SV release in unc-31 mutants was suggested to be an indirect consequence of perturbed DCV secretion. Our data show that mutants with stronger DCV-release defects than unc-31 have no effect on EPSCs. This supports the idea that in C. elegans, as in the mammalian system, UNC-31 may play a direct role in SV priming (19, 36) . In addition, UNC-31 might also be required to regulate DCV numbers, because a deletion of unc-31 in contrast to rab-5/10 causes an accumulation of DCV in axons, which is enhanced in unc-31; rab-10 double mutants (Fig. S2 F and G) . This places RAB-5 and RAB-10, together with PKC-1, into a group of molecules fully dispensable for SV secretion and only required for DCV release.
Our results show that, in neurons, RAB-5 and RAB-10 primarily localize to puncta within the cell body. Based on their localizations, it is likely that these molecules are required at an early stage in the formation of mDCVs. We propose a model by which an iDCV membrane compartment acquires RAB-5-and RAB-10-positive domains that would enable an essential sorting step required for the formation of release-competent mDCVs. Active, GTP-bound RAB-5 molecules recruit their effector, Rabaptin-5/RABN-5, which has been implicated in early endosomal fusion (31) . RABN-5 exists in a stable complex with Rabex-5/RABX-5 in mammalian cells and C. elegans (37, 38) . Only as a complex is Rabaptin-5 efficiently recruited to endosomes. Thus, local activation of Rab5 would lead to the recruitment of this complex, which would further activate more Rab5 molecules in close proximity causing them to cluster (37) . As demonstrated, this growing domain of active RAB-5 simultaneously eliminates RAB-10 by recruiting the RAB-10 GAP, TBC-4. Our results also showed that active, GTP-bound RAB-10 is able to bind and recruit the RAB-5 GAP, TBC-2, in vivo. Thus, these data also suggest a reciprocal elimination of RAB-5 from active RAB-10 domains. Such a RAB-5/RAB-10 exclusion mechanism would allow two defined membrane subdomains to form from a randomly ordered precursor compartment (Fig. 5E and Fig. S8 ). This mechanism would also allow these domains to be stably maintained on the same membrane patch in close proximity to each other, which is most likely a prerequisite for proper sorting between these domains.
Depletion of RAB-5 and RAB-10 does not affect DCV biogenesis, trafficking, and localization, as revealed by confocal microscopy and HPF-EM imaging (Figs. S2 and S3) . However, the competence of DCVs to fuse is drastically reduced. A major question still remains: what causes the inability of DCVs to be released in rab-5 and rab-10 mutants? The RAB-5/RAB-10 cascade could be required either to sort factors into DCVs for fusion or remove factors that are otherwise inhibitory to DCV release. Likely candidates for such molecules required for the initial steps of DCV biogenesis, which are later sorted away, are Syntaxin-6, vesicle-associated membrane protein (VAMP)4, and Synaptotagmin IV (5) . Specifically in neurons and in neuroendocrine pituitary cells, the presence of Synaptotagmin IV on DCVs has been shown to inhibit DCV release (39) (40) (41) . Thus, these molecules have to be sorted away for efficient release of DCVs.
Alternatively, the RAB-5/RAB-10 cascade could be required to sort specific molecules into DCVs that would be required for proper release. One possibility is that such molecules could be involved in remodeling filamentous (F)-actin at DCV-release sites. In bovine chromaffin cells, it has been shown that DCVs are prevented from accessing the exocytic sites by a barrier of cortical actin (42) . After stimulation, several F-actin-serving pathways have been shown to be activated, facilitating recruitment of DCVs to the plasma membrane (42) . These factors may be recruited directly by RAB-10, because we show that RAB-10 is also found at axonal release sites and perhaps even on DCVs (4, 43) . After exclusion from the RAB-5 domain, RAB-10 could be subsequently recruited to a forming DCV domain. This membrane domain could be specified by the RAB-10 effector, EHBP-1, which is already membrane-localized independent of RAB-10 (32). Thus, EHBP-1 may recruit active RAB-10 to DCVs because elimination of either molecule prevents DCV release in a similar manner. How RAB-10 would be activated close to EHBP-1 is not yet clear. Interestingly, EHBP-1 possesses an actin-binding calponin-homology domain that may bind to actin. Therefore, it is tempting to consider that a reorganization of the actin network around DCVs may be a rate-limiting step for DCV release.
Since a wide range of biological processes are facilitated by DCVs, including neuronal development, blood glucose homeostasis, pain sensation, learning, and memory, a deeper knowledge of DCV-release mechanisms will, therefore, enable the development of specific therapeutic strategies to treat disorders caused by perturbed neuropeptide and insulin function such as diabetes.
Materials and Methods
Most experiments were performed according to previously published procedures and are explained in detail in SI Materials and Methods.
Strains and Genetics. All strains were cultured at 20°C on OP50 Escherichia coli-seeded nematode growth medium (NGM) plates as described previously (44) . All mutant and transgenic strains are described in SI Materials and Methods. Newly generated strains are listed in Tables S1 and S2. 
